For participants who develop a need for a P2Y12 inhibitor (e.g. acute coronary syndrome, percutaneous coronary intervention with stent insertion), the study medication must be discontinued.
For participants who require long-term dual antiplatelet therapy or single antiplatelet therapy with a P2Y12 inhibitor, the study medication must be stopped. Participants who discontinue the study medication will continue with regular study visits.
The study medication can be restarted once dual antiplatelet therapy or single antiplatelet therapy with a P2Y12 inhibitor is stopped or no longer required.
